ORIGINAL ARTICLES   

International Angiology 2004 September;23(3):238-45

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: English

The effect of Liple® on physical and emotional quality of life in the treatment of arteriosclerosis obliterans

Fukuhara S. ¹, Esato K. ²

¹ Department of Epidemiology and Healthcare Research, Kyoto University, Graduate School of Medicine and Public Health, Kyoto, Japan 2 Yamaguchi Prefecture Central Hospital, Yamaguchi, Japan

Aim. The pur­pose of this study was to deter­mine the ­effect of treat­ment with pros­ta­glan­din E1, Liple, on both the phys­i­cal and emo­tion­al ­health-relat­ed qual­ity of life (QOL) of ­patients with arte­rio­scle­ro­sis oblit­e­rans (ASO).
Meth­ods. Treat­ment with Liple was eval­u­at­ed using the ­before and after treat­ment ­results ­obtained using the SF-36, a QOL ques­tion­naire, and an assess­ment of symp­toms by a phy­si­cian. The study was ­designed as a non-ran­dom­ized ­before and after treat­ment study with­out com­par­i­son ­groups, and the study was con­duct­ed from May 1999 to July 2001 at 473 facil­ities locat­ed with­in Japan tar­get­ing ­patients with ASO. No inter­ven­tion other than the admin­is­tra­tion of Liple was per­formed, and no restric­tions were ­placed on the dose ­amount or admin­is­tra­tion inter­val for Liple.
­Results. The ­results sug­gest that there was a sig­nif­i­cant improve­ment in ­patients’ symp­toms after treat­ment with Liple.
Con­clu­sion. Both phys­i­cal and emo­tion­al QOL also ­improved after admis­tra­tion of Liple com­pared to base­line, based on the ­results of the SF-36 and assess­ment of symp­toms by a phy­si­cian.